Aivita Biomedical gets US FDA nod to begin phase II trial of ROOT OF CANCER technology in patients with glioblastoma multiforme

MLA

“Aivita Biomedical Gets US FDA Nod to Begin Phase II Trial of ROOT OF CANCER Technology in Patients with Glioblastoma Multiforme.” PharmaBiz, June 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.543884154&authtype=sso&custid=ns315887.

APA

Aivita Biomedical gets US FDA nod to begin phase II trial of ROOT OF CANCER technology in patients with glioblastoma multiforme. (2018, June 22). PharmaBiz.

Chicago

PharmaBiz. 2018. “Aivita Biomedical Gets US FDA Nod to Begin Phase II Trial of ROOT OF CANCER Technology in Patients with Glioblastoma Multiforme,” June 22. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.543884154&authtype=sso&custid=ns315887.